Current And Forthcoming Parathyroid Disorders Market Size In Terms Of Volume And Value 2023

 Market Scenario:

Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.

According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5451 

Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.

Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the global parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.

Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.

It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Medical Device Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Segmentation

The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.

On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.

On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis:

The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.

The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.

Key Players

Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Necrotizing Fasciitis Market Expected To Grow At High Cagr During Forecast Period 2020 – 2023

 Market Scenario:

Also known as flesh-eating disease, necrotizing fasciitis is a rare bacterial infection affecting the tissue beneath the skin, surrounding muscles, and organs. The bacteria that is responsible for the disease releases toxins results into the damage nearby tissue. There are four major types for necrotizing fasciitis – type I known as polymicrobial infection, type II caused by haemolytic group A streptococcus, staphylococci such as methicillin resistant strains/MRSA, type III caused by bacterium such as clostridium, and others. It starts as a minor injury such as a small cut, but may get worst and can be life threatening if left untreated. Major risk factors for the disease are diabetes, cancer, obesity, intravenous drug use, alcoholism, and peripheral vascular disease. The disease can be prevented by maintaining hygiene which includes proper wound care and hand washing.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5450 

 The global necrotizing fasciitis necrotizing fasciitis market market is majorly driven by the increasing prevalence of cancer, diabetes, continuously increasing geriatric population and increasing number of patients suffering from various bacterial infection. However, the growth of the market is restricted due to lack of awareness about necrotizing fasciitis and high cost of treatment.

The global necrotizing fasciitis market is expected to grow at a CAGR of 6.2% during the forecasted period.

Segments 

• The global necrotizing fasciitis market is segmented on the basis of type, treatment, and end users.

• On the basis of the type, the market is categorized into Type I, Type II, Type III and others.

• On the basis of the treatment, the market is segmented into intravenous antibiotics, surgery, hyperbaric oxygen treatment and others.

• On the basis of the end users, the market is segmented into hospitals & clinics, surgical centers and others.

Regional Analysis

America accounts for the largest share in the global necrotizing fasciitis market owing to presence of key players in the market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, rising awareness about bacterial infection is further set to accelerate the growth of the market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada. In the U.S, the prevalence of cardiovascular disease is found to be increasing from last few years. This is attributed to the rising prevalence of chronic diseases such as obesity and diabetes which are the major risk factors for cardiovascular diseases. As per the Center for Disease Control & Prevention (CDC), in 2015, 28.4 million adults were diagnosed with cardiovascular diseases in the U.S. alone.

Europe is the second largest market and holds a noticeable share in the global necrotizing fasciitis market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities and skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support.

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and bacterial infection in developing countries is the major driver for the market growth. China and India are the fastest growing regions owing to increasing geriatric population. Also, the diabetes is one of the major chronic conditions affecting large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively. It stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the population had hypertension

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness about necrotizing fasciitis, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates holds the largest market share owing to development of healthcare industry and rising availability of specialty care centers.

Key Players

Some of the key players in necrotizing fasciitis market are Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/necrotizing-fasciitis-market-5450

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Top Trends In Lancet and Pen Needles Market By 2023

 Lancet and pen needles can be effectively used for the blood-based diagnosis, monitoring, and medication of diseases like diabetes and osteoporosis.  Pen needles are used in conjunction with the injection pens. Structurally, a pen needle consists of a hollow needle, which is embedded in a plastic hub and attaches to the injection pen. The lancet are double edged blades or needles and appears similar to the small scalpels. The market for lancet and pen needles is expected to grow at a healthy CAGR during the forecast period in the Asia Pacific region due to increasing prevalence of diseases like diabetes and osteoporosis. According to a study conducted by the American Diabetes Association in 2016, about 80% of the diabetic patients resides in the developing countries and it is estimated that the rise of type 2 diabetes in South Asia is likely to be 150% between 2000 and 2035. Moreover, in the Western Pacific region, the number of diabetic patients is expected to reach 201.8 million by 2035. Additionally, according to the International Osteoporosis Foundation by 2050, over ~50% of all osteoporotic hip fractures are expected to occur in Asia. Factors such as increasing geriatric population and growing healthcare expenditure along with favourable government policies are projected to boost the market growth during the forecast period.  However, the need to remove the pin after a single use and high cost as compared to the insulin vials may restrain the market growth during the forecast period. 

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/630

The Asia Pacific lancet and pen needles market is expected to grow at an approximate CAGR of 6.5% during the forecast period, 2017-2023.  

Segmentation

The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.

On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.

On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.

On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.

 

Regional Analysis

On the regional basis, Asia Pacific is segmented into Japan, India, China, the Republic of Korea, Australia, and the Rest of Asia Pacific.

Japan holds a major share of the market followed by the Republic of Korea and Australia owing to the well-developed healthcare sector and high per capita healthcare expenditure. In 2014, according to the Statistics Bureau, Japan’s total medical care expenditure was about 11.20% of the national income, which accounted for USD 0.37 trillion. Additionally, favorable governmental policies boost the market growth in these regions.

China and India have a growing market due to huge population base, increasing demand for the better quality products, rapidly changing the economy, increasing healthcare expenditure, and rising number of pharmaceutical & biotechnological companies. Moreover, increasing number of healthcare organizations like a hospital, the private research institute has led to increasing in the market in India. Rest of Asia Pacific holds the least share of the market. 

Key players for Asia Pacific lancet and pen needles market

Some of the key players in the Asia Pacific lancet and pen needles market are BD. (U.S.), Novo Nordisk A/S (Europe), Ypsomed (Europe), B. Braun Melsungen AG (Europe), HTL-STREFA (Europe), Terumo Corporation (Asia Pacific), Artsana S.p.A. (Europe), Owen Mumford Ltd. (Europe), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asia-pacific-lancet-pen-needels-market-630

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Sterility Testing Market Trends, Analysis And Review During 2020 To 2023

 The global sterility testing market is anticipated to reach USD 1,245.2 million by 2023, as per a new detailed report by Market Research Future (MRFR). It is expected to exhibit an 11.7% CAGR during the assessment period (2017-2023). High prevalence of cardiovascular diseases and various cancers are expected to induce market demand. Government support in terms of funding coupled with the expanding life science sector is anticipated to bode well for the market during the forecast period.

Sterility testing is essential for research and development purposes in pharmaceutical companies. It is a crucial step for determining the safety of drugs before consumption. In addition, sterility testing is also conducted in specific rooms in facilities to keep it germ-resistant. Drugs and vaccines undergone sterility testing can be commoditized and made commercially available to the masses. This can be beneficial to patients afflicted with cancer and cardiovascular diseases.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/547

Report Overview

This report allows the user to gain a deeper understanding of the ongoing events and trends in the global market for sterility testing. By correlating the historical data with key market dynamics, analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global sterility testing market segmented by product type, test type, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.

Segment Overview

By product type, the sterility testing market has been segmented into instruments, consumables, and services. The services segment is further segmented into sterility assurance tests, sterility validations, cleaning and disinfection, and stability testing. By test type, the market is segmented into product flush sterility testing, membrane filtration sterility testing, direct transfer sterility testing, and others. By end-user, the market is segmented into academic and research laboratories, pharmaceutical companies, hospitals and clinics, and others.  

The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “sterility testing” is included in the report. The report discusses and interprets the current and future opportunities of the industry delivering an unbiased growth assessment.

Players Covered

Bioquell U.K. Ltd., Belimed Deutschland GmbH, Baxter BioPharma Solutions, Charles River Laboratories Inc., Boston Scientific Corporation, BioMérieux SA, Thermo Fisher Scientific Inc., SGS SA, Pacific BioLabs Inc., WuXi AppTec, Astell Scientific, Sartorius AG, Becton, Dickinson and Company, Merck KGaA, and others are prominent players in the sterility testing market.

The report offers comprehensive profiles on these market players and assesses their current standing in the sterility testing market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.

Research Methodology

Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report consists of news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/sterility-testing-market-547

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Ischemic stroke Market Segmentation Detailed Study With Forecast Up To 2023

 Market Scenario

Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.

The key strategies adopted by leading industry players incldues new product launches and collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization (TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This minimally invasive technique is designed to access the common carotid artery. Moreover, in March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial fibrillation received FDA approval.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5423

Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke treatment. Increasing demand for minimally invasive procedures and advancements in surgical procedures are the key factors boosting the growth of the global ischemic stroke market. High cost of the surgical procedures and excessive usage of medication for the treatment of ischemic stroke are hindering the market growth.

The global market for ischemic stroke is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.

Intended Audience:

• Ischemic Stroke Drug Suppliers
• Ischemic Stroke Drug Manufacturers
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation:

The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.

On the basis of the drug class, the market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and others

On the basis of the surgery, the market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis:                     

The global ischemic stroke market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has emerged as the largest market for the global ischemic stroke owing to the favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products. According to the American Heart Association, ischemic stroke is among the top three causes of death in the U.S. and Canada, nearly 795,000 patients suffering from strokes are treated in the 2014.

Europe is the second largest global ischemic stroke market owing to the advancements in the surgical devices technology along with the rising occurrence of acute ischemia stroke cases among the patients. In the European Union, over 31 million people are living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. Some other factors driving the market includes the growing percentage of diabetes mellitus population mainly in the developed countries of Europe

Asia Pacific is anticipated to unfold as the most promising market for the global ischemic stroke owing to increasing prevalence of stroke cases in this region. China and India are considered as a big market for ischemic stroke within the forecast period. Manufacturers are expanding their operations in Asia Pacific region as these regions hold immense potential for the market growth.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ischemic-stroke-market-5423

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Obstructive Lung Disease Market Dynamics, Forecast, Analysis And Supply Demand 2023

 Market Scenario

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5367

As per the Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as an occupational hazard in people working in agriculture, mining, plastics, and other industries.

Governments across each country have implemented regulations for the production, standardization, and utilization of COPD devices. These devices are divided into categories –Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.

However, stringent government regulatory requirement for the approval of asthma and COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs restrict the market growth.

The global market of obstructive lung disease is expected to grow at a CAGR of approximately 8.5% during the forecast period 2017-2023.

Intended Audience

• Obstructive Lung Disease Drug Suppliers
• Obstructive Lung Disease Drug Manufacturers
• Obstructive Lung Disease Device Suppliers
• Obstructive Lung Disease Device Manufacturers
• Research And Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation

The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.

On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others 

On the basis of product type market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers

On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.

On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Key Players

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.

Some of key the players in the global obstructive lung disease market are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. Inc. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.),  Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obstructive-lung-disease-market-5367

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Moyamoya Disease Market, Segments, Growth And Value Chain Analysis 2023

 Market Scenario

Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5275

According to the National Organization for Rare Diseases, in Japan, moyamoya disease is estimated to occur in 1 per 1 million people, and the condition is more prevalent in females under the age of 20. It is also reported that nearly 10% of cases of moyamoya disease in Asian countries have a genetic cause. Recently, two major mutations have been found to be associated with a specific population of moyamoya patients i.e. R179, and RNF213 mutations.

Intended Audience

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Key Players

Some of key the players in the global moyamoya disease market are Abbott Laboratories, Boston Scientific Corporation, Cephalon, Inc., Cordis Corporation, Eisai Co., Ltd, GE Healthcare, Genentech Inc., GlaxoSmithKline PLC., Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Siemens, Stryker,, Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Valeant Pharmaceuticals International, Inc. and others.

It is noted that growing public awareness and technological advancements are the key factors driving the moyamoya disease market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and health conscious. Thus, increasing awareness has provided a push to the growth of the market. The new and existing marketers are also contributing to control this condition. For instance, on April 13, 2016, Silk Road Medical, Inc., received FDA approval for its next-generation ENROUTE Transcarotid Neuroprotection System (NPS). The NPS is specifically designed and indicated for transcarotid artery revascularization.

Various other factors such as increased incidence of neurological disorders, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the global moyamoya disease market.

Despite these drivers, there are some issues associated with moyamoya disease market. The challenges in research and development, cost of treatment, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.

It is estimated that the moyamoya disease market is expected to grow at a CAGR 7.0% during the forecast period of 2017-2023.

Segmentation

The global moyamoya disease market is segmented on the basis of diagnosis, treatment, and distribution channels.

On the basis of the diagnosis, the market is classified as a cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance angiogram (MRA), computed tomography (CT) scans, transcranial Doppler ultrasound, positron emission tomography (PET) scan, and electroencephalography (EEG).

On the basis of the treatment, the market is classified as surgical treatment and non-surgical treatment. The surgical treatment is further classified as pial synangiosis, indirect procedures, and direct arterial bypass. The sub-segment of indirect procedures includes EDAS (encephaloduroarteriosynangiosis), EMS (encephalomyosynangiosis), Omental transposition/transfer, and dural inversion. The non-surgical treatment is further classified as anticoagulation and antiplatelet therapy, and others. The sub-segment of anticoagulation and antiplatelet therapy include heparin, warfarin, aspirin, and others.

On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies and others.

Regional Analysis

The Americas dominate the moyamoya disease market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the moyamoya disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive European market.

The Asia Pacific is the fastest growing moyamoya disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015

The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/moyamoya-disease-market-5275 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com